ICI-164384
ICI-164384 is a nonsteroidal antiestrogen
| Drug Information | |||
|---|---|---|---|
| Image | |||
| Identifiers
CAS Number ATC Code PubChem DrugBank ChemSpider ID UNII KEGG ChEBI ChEMBL IUPAC Name |
Chemical Data
C H N O Molecular Weight | ||
ICI-164384 is a nonsteroidal antiestrogen that was developed for the treatment of breast cancer. It is a member of the class of compounds known as selective estrogen receptor modulators (SERMs). Unlike other SERMs, ICI-164384 acts as a pure antiestrogen, meaning it does not exhibit any estrogen-like effects in tissues.
Mechanism of Action[edit | edit source]
ICI-164384 works by binding to the estrogen receptors (ERs) in breast tissue, thereby blocking the effects of estrogen. This inhibition prevents the growth and proliferation of estrogen receptor-positive breast cancer cells. The compound has a high affinity for the ER, making it a potent antiestrogen.
Clinical Use[edit | edit source]
Although ICI-164384 showed promise in preclinical studies, it was never marketed for clinical use. However, its development has contributed to the understanding of estrogen receptor modulation and has paved the way for the development of other antiestrogens, such as fulvestrant.
Research[edit | edit source]
ICI-164384 has been extensively studied in preclinical models to understand its effects on estrogen receptor signaling. Research has shown that it can effectively inhibit the growth of breast cancer cells in vitro and in vivo. Studies have also explored its potential use in combination with other anticancer drugs to enhance therapeutic efficacy.
Related Compounds[edit | edit source]
ICI-164384 is structurally related to other antiestrogens, including tamoxifen and raloxifene. However, unlike these compounds, ICI-164384 does not have any partial agonist activity, making it a pure antiestrogen.
See Also[edit | edit source]
- Selective estrogen receptor modulator
- Estrogen receptor
- Breast cancer
- Fulvestrant
- Tamoxifen
- Raloxifene
References[edit | edit source]
External Links[edit | edit source]
 | This medical article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
